Cell Therapeutics Inc (NASDAQ:CTIC) selling preferred stock


Dallas, Texas 09/18/2013 (Financialstrend) – Cell Therapeutics Inc (NASDAQ:CTIC), the biopharma company is selling 15,000 shares of Series-18 preferred stock directly to a Perceptive Advisors LLC affiliate and Quogue Capital LLC for gross-proceeds of $15M in a registered direct-offering.

After deducting all estimated offering-expenses, the net proceeds of the offering will amount to around $14.8 million.

The company added that each share of Series-18 preferred stock will have a $1,000/share stated-value. It will be convertible at the holder’s choice, at any time before the automatic-conversion of such shares in specific circumstances, into 15 million registered common-shares at a conversion-price of $1.00/share of common-stock.

Sale proceeds

Cell Therapeutics Inc (NASDAQ:CTIC)will use the net proceeds of this sale  to continue the pacritinib PhaseIII trials and to support  commercialization of PIXUVRI in Europe, Funding R&D, general corporate purposes, clinical and preclinical trials, the preparation and filing of NDA’s as well as general working capital.

Tuesday’s trading

In Tuesday’s trading session Cell Therapeutics Inc (NASDAQ:CTIC) stock rose by 10.48%. The opening price of the shares was $1.23 which climbed to an intraday high of $1.49 and dipped to close at $1.37. Approximately 5.96 million shares exchanged hands on Tuesday and the average-volume of shares traded over a 30 day period was 1.08 million. The company has a market cap of $157.24 million.

About the company

Cell Therapeutics Inc (NASDAQ:CTIC) is a bio-pharma company. It focuses on acquiring, developing and commercializing less-toxic methods to treat cancer. It is channelizing its efforts on various treatments that target different blood-related cancers where there is a vast unmet medical need. It primarily focuses on the commercialization of PIXUVRI in the EU. This is use for multiplie-relapsed or refractory-aggressive non-Hodgkin lymphoma and is also conducting a Phase-III clinical trial of the drug, pacritinib for myelofibrosis treatment.